Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type

Amy J. VanMeter, Adrianna S. Rodriguez, Elise D. Bowman, Jin Jen, Curtis C. Harris, Jianghong Deng, Valerie S. Calvert, Alessandra Silvestri, Claudia Fredolini, Vikas Chandhoke, Emanuel F. Petricoin, Lance A. Liotta, Virginia Espina

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment. We quantitatively profiled the phosphorylation and abundance of signal pathway proteins relevant to the EGF receptor within laser capture microdissected untreated, human non-small cell lung cancer (NSCLC) (n = 25) of known epidermal growth factor receptor (EGFR) tyrosine kinase domain mutation status. We measured six phosphorylation sites on EGFR to evaluate whether EGFR mutation status in vivo was associated with the coordinated phosphorylation of specific multiple phosphorylation sites on the EGFR and down-stream proteins. Reverse phase protein array quantitation of NSCLC revealed simultaneous increased phosphorylation of EGFR residues Tyr-1148 (p < 0.044) and Tyr-1068 (p < 0.026) and decreased phosphorylation of EGFR Tyr-1045 (p < 0.002), HER2 Tyr-1248 (p < 0.015), IRS-1 Ser-612 (p < 0.001), and SMAD Ser-465/467 (p < 0.011) across all classes of mutated EGFR patient samples compared with wild type. To explore which subset of correlations was influenced by ligand induction versus an intrinsic phenotype of the EGFR mutants, we profiled the time course of 115 cellular signal proteins for EGF ligand-stimulated (three dosages) NSCLC mutant and wild type cultured cell lines. EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Persistence of phosphorylation for AKT Ser-473 following ligand stimulation was found for the mutant. These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor β suppression, and reduced ubiquidnation/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. This is the first comparison of multiple, site-specific phosphoproteins with the EGFR tyrosine kinase domain mutation status in vivo.

Original languageEnglish (US)
Pages (from-to)1902-1924
Number of pages23
JournalMolecular and Cellular Proteomics
Volume7
Issue number10
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Microdissection
Laser Capture Microdissection
Protein Array Analysis
Phosphorylation
Microarrays
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Cells
Lasers
Proteins
Ligands
Epidermal Growth Factor
Protein-Tyrosine Kinases
Mutation
Phosphatidylinositol 3-Kinase
Tissue
Carcinoma
Cell Line
Proto-Oncogene Proteins c-akt

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Analytical Chemistry

Cite this

Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer : Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. / VanMeter, Amy J.; Rodriguez, Adrianna S.; Bowman, Elise D.; Jen, Jin; Harris, Curtis C.; Deng, Jianghong; Calvert, Valerie S.; Silvestri, Alessandra; Fredolini, Claudia; Chandhoke, Vikas; Petricoin, Emanuel F.; Liotta, Lance A.; Espina, Virginia.

In: Molecular and Cellular Proteomics, Vol. 7, No. 10, 10.2008, p. 1902-1924.

Research output: Contribution to journalArticle

VanMeter, AJ, Rodriguez, AS, Bowman, ED, Jen, J, Harris, CC, Deng, J, Calvert, VS, Silvestri, A, Fredolini, C, Chandhoke, V, Petricoin, EF, Liotta, LA & Espina, V 2008, 'Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type', Molecular and Cellular Proteomics, vol. 7, no. 10, pp. 1902-1924. https://doi.org/10.1074/mcp.M800204-MCP200
VanMeter, Amy J. ; Rodriguez, Adrianna S. ; Bowman, Elise D. ; Jen, Jin ; Harris, Curtis C. ; Deng, Jianghong ; Calvert, Valerie S. ; Silvestri, Alessandra ; Fredolini, Claudia ; Chandhoke, Vikas ; Petricoin, Emanuel F. ; Liotta, Lance A. ; Espina, Virginia. / Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer : Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. In: Molecular and Cellular Proteomics. 2008 ; Vol. 7, No. 10. pp. 1902-1924.
@article{30b1762af1744e56a79a31ca2dedf877,
title = "Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type",
abstract = "Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment. We quantitatively profiled the phosphorylation and abundance of signal pathway proteins relevant to the EGF receptor within laser capture microdissected untreated, human non-small cell lung cancer (NSCLC) (n = 25) of known epidermal growth factor receptor (EGFR) tyrosine kinase domain mutation status. We measured six phosphorylation sites on EGFR to evaluate whether EGFR mutation status in vivo was associated with the coordinated phosphorylation of specific multiple phosphorylation sites on the EGFR and down-stream proteins. Reverse phase protein array quantitation of NSCLC revealed simultaneous increased phosphorylation of EGFR residues Tyr-1148 (p < 0.044) and Tyr-1068 (p < 0.026) and decreased phosphorylation of EGFR Tyr-1045 (p < 0.002), HER2 Tyr-1248 (p < 0.015), IRS-1 Ser-612 (p < 0.001), and SMAD Ser-465/467 (p < 0.011) across all classes of mutated EGFR patient samples compared with wild type. To explore which subset of correlations was influenced by ligand induction versus an intrinsic phenotype of the EGFR mutants, we profiled the time course of 115 cellular signal proteins for EGF ligand-stimulated (three dosages) NSCLC mutant and wild type cultured cell lines. EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Persistence of phosphorylation for AKT Ser-473 following ligand stimulation was found for the mutant. These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor β suppression, and reduced ubiquidnation/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. This is the first comparison of multiple, site-specific phosphoproteins with the EGFR tyrosine kinase domain mutation status in vivo.",
author = "VanMeter, {Amy J.} and Rodriguez, {Adrianna S.} and Bowman, {Elise D.} and Jin Jen and Harris, {Curtis C.} and Jianghong Deng and Calvert, {Valerie S.} and Alessandra Silvestri and Claudia Fredolini and Vikas Chandhoke and Petricoin, {Emanuel F.} and Liotta, {Lance A.} and Virginia Espina",
year = "2008",
month = "10",
doi = "10.1074/mcp.M800204-MCP200",
language = "English (US)",
volume = "7",
pages = "1902--1924",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "10",

}

TY - JOUR

T1 - Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer

T2 - Differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type

AU - VanMeter, Amy J.

AU - Rodriguez, Adrianna S.

AU - Bowman, Elise D.

AU - Jen, Jin

AU - Harris, Curtis C.

AU - Deng, Jianghong

AU - Calvert, Valerie S.

AU - Silvestri, Alessandra

AU - Fredolini, Claudia

AU - Chandhoke, Vikas

AU - Petricoin, Emanuel F.

AU - Liotta, Lance A.

AU - Espina, Virginia

PY - 2008/10

Y1 - 2008/10

N2 - Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment. We quantitatively profiled the phosphorylation and abundance of signal pathway proteins relevant to the EGF receptor within laser capture microdissected untreated, human non-small cell lung cancer (NSCLC) (n = 25) of known epidermal growth factor receptor (EGFR) tyrosine kinase domain mutation status. We measured six phosphorylation sites on EGFR to evaluate whether EGFR mutation status in vivo was associated with the coordinated phosphorylation of specific multiple phosphorylation sites on the EGFR and down-stream proteins. Reverse phase protein array quantitation of NSCLC revealed simultaneous increased phosphorylation of EGFR residues Tyr-1148 (p < 0.044) and Tyr-1068 (p < 0.026) and decreased phosphorylation of EGFR Tyr-1045 (p < 0.002), HER2 Tyr-1248 (p < 0.015), IRS-1 Ser-612 (p < 0.001), and SMAD Ser-465/467 (p < 0.011) across all classes of mutated EGFR patient samples compared with wild type. To explore which subset of correlations was influenced by ligand induction versus an intrinsic phenotype of the EGFR mutants, we profiled the time course of 115 cellular signal proteins for EGF ligand-stimulated (three dosages) NSCLC mutant and wild type cultured cell lines. EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Persistence of phosphorylation for AKT Ser-473 following ligand stimulation was found for the mutant. These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor β suppression, and reduced ubiquidnation/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. This is the first comparison of multiple, site-specific phosphoproteins with the EGFR tyrosine kinase domain mutation status in vivo.

AB - Little is known about lung carcinoma epidermal growth factor (EGF) kinase pathway signaling within the context of the tissue microenvironment. We quantitatively profiled the phosphorylation and abundance of signal pathway proteins relevant to the EGF receptor within laser capture microdissected untreated, human non-small cell lung cancer (NSCLC) (n = 25) of known epidermal growth factor receptor (EGFR) tyrosine kinase domain mutation status. We measured six phosphorylation sites on EGFR to evaluate whether EGFR mutation status in vivo was associated with the coordinated phosphorylation of specific multiple phosphorylation sites on the EGFR and down-stream proteins. Reverse phase protein array quantitation of NSCLC revealed simultaneous increased phosphorylation of EGFR residues Tyr-1148 (p < 0.044) and Tyr-1068 (p < 0.026) and decreased phosphorylation of EGFR Tyr-1045 (p < 0.002), HER2 Tyr-1248 (p < 0.015), IRS-1 Ser-612 (p < 0.001), and SMAD Ser-465/467 (p < 0.011) across all classes of mutated EGFR patient samples compared with wild type. To explore which subset of correlations was influenced by ligand induction versus an intrinsic phenotype of the EGFR mutants, we profiled the time course of 115 cellular signal proteins for EGF ligand-stimulated (three dosages) NSCLC mutant and wild type cultured cell lines. EGFR mutant cell lines (H1975 L858R) displayed a pattern of EGFR Tyr-1045 and HER2 Tyr-1248 phosphorylation similar to that found in tissue. Persistence of phosphorylation for AKT Ser-473 following ligand stimulation was found for the mutant. These data suggest that a higher proportion of the EGFR mutant carcinoma cells may exhibit activation of the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin (MTOR) pathway through Tyr-1148 and Tyr-1068 and suppression of IRS-1 Ser-612, altered heterodimerization with ERBB2, reduced response to transforming growth factor β suppression, and reduced ubiquidnation/degradation of the EGFR through EGFR Tyr-1045, thus providing a survival advantage. This is the first comparison of multiple, site-specific phosphoproteins with the EGFR tyrosine kinase domain mutation status in vivo.

UR - http://www.scopus.com/inward/record.url?scp=55049137476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049137476&partnerID=8YFLogxK

U2 - 10.1074/mcp.M800204-MCP200

DO - 10.1074/mcp.M800204-MCP200

M3 - Article

C2 - 18687633

AN - SCOPUS:55049137476

VL - 7

SP - 1902

EP - 1924

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 10

ER -